Loading organizations...
Biovest International, Inc. develops personalized active immunotherapies, such as BiovaxID, to treat specific blood cancers like B-cell non-Hodgkin's lymphoma. It also offers specialized cell culture products, instruments, and contract manufacturing services, providing solutions for high cell density applications in biotech, pharma, and research.
Founded in 1981 by Kyriakides, Biovest International originated from the insight that the immune system could be precisely mobilized to combat specific malignancies. This principle has driven development of biotechnology products and targeted therapeutic strategies, solidifying expertise in personalized oncology.
Biovest’s offerings cater to biotech, pharma, and research communities, with therapies directly addressing oncology patient needs. The company aims to advance personalized biopharmaceutical solutions, striving to improve outcomes for individuals battling complex cancers and supporting scientific progress through manufacturing and cell culture capabilities.
Key people at Biovest.
Biovest was founded in 1986 by Christopher Kyriakides (Founder).
Biovest has 3 tracked investments across 2 companies. The latest tracked deal is $39.0M Series C in Biotalys in July 2019.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 30, 2019 | Biotalys | $39.0M Series C | — | Piet Bevernage, Agri Investment Fund, GIMV, K&E, Madeli Participaties, PMV, Qbic, Sofinnova Partners |
| Mar 9, 2017 | Biotalys | $11.7M Series B Extension | — | Agri Investment Fund, GIMV, Globachem Group, Madeli Participaties, PMV, Qbic, Sofinnova Partners, VIB |
| Apr 1, 2010 | Biocartis | $40.0M Series B | Dinko Valerio | Advent Life Sciences, Advent Venture Partners, Rudi Pauwels, Pietro Scalfaro, Johnson & Johnson Innovation |
Key people at Biovest.
